Our results showed that MIP-1β was obviously elevated in NSCLC patients after radiotherapy, in comparison with these patients before radiotherapy, and there were more expressions of RANTES and I-309 of NSCLC patients in the post-RT group than in the HC group. The gene discussed is CCL4; the disease is non-small cell lung carcinoma.